Janux Therapeutics, Inc. (JANX) Commences Patient Dosing of JANX011 in Autoimmune Trial
Janux Therapeutics Inc. (NASDAQ: JANX) is one of the best cancer stocks to invest in now. On February 17, Janux Therapeutics Inc.
Janux Therapeutics Inc. (JANX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 3 | $42 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.02 | 110,206 | $3,418,590.12 | 10,141,287 | 2025-03-07 | Filing | |
| $30.78 | 372,093 | $11,453,022.54 | 10,031,081 | 2025-03-06 | Filing | |
| $31.30 | 37,455 | $1,172,341.50 | 9,658,988 | 2025-03-05 | Filing | |
| $30.56 | 304,287 | $9,299,010.72 | 9,621,533 | 2025-03-05 | Filing | |
| $44.75 | 1,200,000 | $53,700,000.00 | 9,317,246 | 2024-10-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.73 | 1,879 | $25,798.67 | 83,095 | 2026-01-02 | Filing | |
| $13.73 | 2,505 | $34,393.65 | 124,425 | 2026-01-02 | Filing | |
| $13.73 | 8,072 | $110,828.56 | 284,982 | 2026-01-02 | Filing | |
| $13.73 | 2,401 | $32,965.73 | 77,721 | 2026-01-02 | Filing | |
| $13.73 | 2,714 | $37,263.22 | 23,286 | 2026-01-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 66,867 | $929,451 | 0.01% | |
| 2. | 51,189 | $711,527 | 0.05% | |
| 3. | 2,044 | $28,412 | 0% | |
| 4. | 1,831 | $25,451 | 0% | |
| 5. | 1,342 | $18,654 | 0% |
News See All
11 Best Cancer Stocks to Invest In Now
Pharmaceutical companies are a blend of defensive income plays and growth opportunities.
Where is Janux Therapeutics (JANX) Headed According to Analysts?
Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the best immunotherapy stocks to buy according to hedge funds. JonesTrading maintained a Buy rating on Janux Therapeutics, Inc.
12 Best Immunotherapy Stocks to Buy According to Hedge Funds
On February 13, Matt Orton, Raymond James Investment Management's chief market strategist, appeared on CNBC’s ‘The Exchange’ to talk about the recent trends in equity markets and what may drive ...
Janux Therapeutics, Inc. (JANX) Faces Platform Risk Amid Lack of Durability Data on JANX007
TheFly reported on January 20 that Clear Street downgraded JANX to Hold from Buy and lowered the price target to $12 from $32.
20 Best Biotech Stocks Under $20 to Buy Now
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (NASDAQ:JANX) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, Janux Therapeutics, Inc.
13 Best Get Rich Fast Stocks to Buy Right Now
In today's fast-paced world, everyone is prioritising investments that have both high and relatively quick returns.
Jones Trading Remains Bullish on Janux Therapeutics (JANX) Amid Promising Developments in Prostate Cancer Program
On November 11, 2025, Jones Trading’s Soumit Roy reiterated his “Buy” rating on Janux Therapeutics, Inc.
10 Best Small-Cap Biotech Stocks to Buy According to Analysts
Small-cap biotech stocks are marking their latest resurgence, attracting renewed investor attention.
Hedge Fund Resource Center